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SURVIVAL FOLLOWING LOCOREGIONAL RECURRENT 
BREAST CANCER - RESULTS FROM A PROSPECTIVE 
STUDY WITH MORE THAN 10 YEARS OF FOLLOW-UP.
C. Kamby, L. Sengel0v 
Finsen Centre, Rigshospitalet and Department of Oncology 
Copenhagen University Hospital in Herlev, Denmark.
We evaluated prognostic factors for survival after locoregional 
recurrence (SAR) in 140 patients (pts) with breast cancer. The 
patients were entered in a staging protocol for pts with first recurrence 
of breast cancer in the period 1983-85. If possible, the pts received 
local treatment (surgery or radiotherapy). The aim was to identify pts 
with long survival by relating the duration of SAR to therapeutic, 
demographic, biological and pathological variables. Local treatment 
was given to 99 pts. As of Feb. 1995, 78 pts had developed distant 
metastases and 93 pts had died. The median SAR was 67 months and 
30% were alive after 10 years (38% for local and 18% for systemic 
therapy, p=0.004). Nine potential prognostic factors for SAR 
(p<0.25) were included in Cox analyses. S-lactate dehydrogenase 
(LDH) and the number of positive regional nodes (Npos) were 
significant independent prognostic factors. A prognostic index with 3 
groups showed the following survival rates at 10 years; 49% (normal 
LDH and Npos=0); 29% (normal LDH and Npos>0 or elevated LDH 
and Npos=0); 12% (elevated LDH and Npos>0. The study showed 
that one third of the pts was alive and without distant metastases ten 
years aftei locoregional recurrence, SAR can be estimated by level of 
LDH and regional node status. These variables may be used to 
stratify pts in future studies evaluating locoregional treatments.
Prophylactic mastectomy is not a self-evident choice for women 
carrying a germ line BRCA1 or BRCA2 mutation: description and 
first results of a decision support procedure.
Lia C.G. Verhoef*, Ivana J. Unic*, Peep F.M. Stalmeier**, Willem A.J. 
van Daal* and the Nijmegen Breast Cancer Working Party.
*Institute of Radiotherapy and the **Nijmegen Institute for Cognition 
and Information, University of Nijmegen, The Netherlands.
Background . The cloning of the breast/ovarian cancer susceptibility 
genes BRCA1 and BRCA2 has led to the identification of a group of 
healthy women carrying an extremely high breast cancer risk (85%). 
Bilateral prophylactic mastectomy (PM) is often suggested as a 
preventive measure in these women.
Purpose. To develop and evaluate a decision support procedure to 
assist women in the choice between PM and screening.
Methods, With a decision model, using Markov processes of medical 
prognosis, PM and screening are compared with respect to their effect 
on life-expectancy (LE) and quality-adjusted life-expectancy (QALE). 
The risks to develop breast cancer and to die from it after both options 
are modeled. The gene carriers were provided with extensive oral» 
written and audiovisual information. Each individual woman's 
subjective valuations of life after PM and with screening (utilities) are 
assessed at at least two occasions by means of the time tradeoff test and 
the certainty equivalent method. The resulting utilities are implemented 
into the model, so that for each individual woman the effect of both 
choices on (quality-adjusted) LE can be estimated. The option whith 
the highest QALE is the best choice.
Results. Seven women with a proven BRCA1 or BRCA2 mutation 
completed the decision support procedure. For all women, the 
estimated LE was higher after PM than with screening (median gain 9.7 
yrs, range 3.4-11.4 yrs.). However, in only 4 women the estimated 
QALE was better after PM (median gain 2,1 QALY'S, range -8.2 - +13 
QALY's). Therefore, the best choice according to the decision support 
procedure was screening in 3 cases and PM in 4 cases. Five women 
made a final choice: 3 times screening, 2 times PM. All were conform 
the decision analytic advice, even though the advice of the Breast 
Cancer Working Party is PM in all gene carriers. All 5 felt supported in 
their decision by the decision support procedure. The 2 remaining 
women have not yet decided.
C onclusions . Our preliminary results indicate, that it is far from 
obvious that PM is the best choice for these women if quality of life is 
taken into account. Formal decision analytic support may help to 
ascertain that the patients' own values play an appropriate role in the 
Final decision.
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RADIOTHERAPY AFTER OPERATION OF BREAST 
CANCER : THE QUESTION OF "SAFE OMISSION"
J* Fodor, M.PAIfi
National institute of Oncology Dept, of Radiotherapy, Budapest, Hungary
Background: Till now there has been no consensus on the use of 
post-mastectomy adjuvant irradiation. Even the usefulness of radiotherapy 
(RT) after breast conserving surgery has been discussed recently, and 
omission is suggested in early cases. Purpose: The aim of this study is to 
define which patients need or do not need adjuvant RT. Patients and 
Methods: In this study between 1983 and 1988, 1040 women were 
surgically treated by mastectomy (826) or by sector resection (214) and in 
both of these cases axillary dissection was performed. For statistical 
analysis, patients with the same pTpN status were assigned to subgroups 
according to whether they received adjuvant RT or didn't. The impact of 
intraductal components cm the local relapses was also analysed. Results: 
\J  Mastectomy group: Patients with pTlpNO status after RT had 2% 
chest wall-sear relapses and the rate of recurrence was 5% in the untreated 
cases. Irradiated women with pT2pN0 status had significantly better 
results than unirradiated ones. The relapse rate was 5% and 10% 
respectively. 2,/ Breast conserving group: with pTl-2N0 status the 
percentage of tumor-bed relapse was 10% in the irradiated and 31 % in the 
untreated group. However the rate o f relapse was the highest with pTlto 
status in both groups, 13% and 46% respectively. One possible 
explanation for this is that the extended intraductal component was most 
frequently found in this status and therefore had an impact on tumor-bed 
relapses. The recurrence rate was 43% with extensive intraductal 
component and 7% without. Conclusion: After mastectomy the cut off 
tumor diameter of local relapses was > 2 cm. Under this tumor size the 
recurrence rate was < 5% in both groups. After breast conserving surgery 
there is not a cut off tumor diameter in the invasive breast cancer. 
Irradiation can not be safely omitted even with minimal < 1 cm. breast 
cancer.
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CONSERVATIVE TREATMENT OF BREAST CANCER: 
MORBIDITY OP RADIOTHERAPY
ttOREHO F ■ MARTI NEZ K, RODRIGUE? D, G0ME2 J, POLO A, RUBIO E, VILLA S, GUTLERREZ C, PETRIZ l, PERA J.Radiation Oncology. fnatîtut Català D'Oncologia. C.S.U. de Bellvltge. L'Hospitalet de Lt. (Barcelona). Spain
Purpose: To asses the morbidity of radiotherapy 
in women with breast conservative treatment. 
Methods and Materials; Medical records of 1007 
women with stage I and II breast cancer who 
were treated in our Institution from 11/1982 to 
12/1995 have been analyzed. All women received 
limited breast surgery (LS), axillary 
dissection and radiation therapy (RT). The mean 
age was 52 years (r23-86). Ductal infiltrant 
carcinoma was present in 94% of the patients; 
other types were found in 6%. After LS, the 
mean doses received were 50Gy in the whole 
breast and 18Gy in the tumoral bed as a boost 
irradiation. Adjuvant chelno-hormonotherapy was 
administrated to 47% of the patients.
Results ; arm edema was present in 5.6% of the 
cases, brachial plexopathy in 1%, neumonitis in 
0.9% and unresolved skin changes in 25%; 
infectious mastitis was observed in 1.8% of the 
patients who received brachitherapy.
Conclus Iona : our incidence of neumonitis was 
low; arm edema and brachial plexopathy were 
independent of axillary and supraclavicular 
irradiation; interstitial boost increases 
cutaneous pigmentation and, perhaps it has a 
role in infectious mastitis.
